Moclobemide Twice Daily in the Treatment of Major Depressive Episode: A Double-Blind, Multicenter Comparison with Different Three-Times-Daily Dosage Schedules

Gagiano, C. A.; Hart, Gili; Bodemer, W.; Schall, Robert

doi:10.1097/00002826-199417001-00002

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ment combining efficacy and tolerability was rated as good or very good for 85% of patients. Gagiano et al (1994) reported on a 6-month, open-label study of MOC continuation therapy (300-450 mg/day). Just 6 of 81 patients (7.5%) relapsed, although another 10 patients (12%) were lost to follow-up.…”

Section: Moclobemide Versus Ssrismentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

139

View full text Add to dashboard Cite

Section: Moclobemide Versus Ssrismentioning

confidence: 99%

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Lotufo-Neto

1999

Neuropsychopharmacology

139

View full text Add to dashboard Cite

“…Angst et al 1993;Gagiano et al 1995; both investigated moclobemide) with their focus on anxiety-related symptoms. However, comparisons with the activity profiles of other antidepressants should be regarded as preliminary since published information on subscale findings is quite sparse.…”

Section: Discussionmentioning

confidence: 99%

Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials

Kasper

Dienel

2002

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…In a six-month, open-label study of moclobemide-continuation treatment (300 to 450 mg) 6 of 81 patients (7.5%) relapsed, although another 10 patients (12%) were lost during follow-up (89). From this study a sustained efficacy across 6 months of continuation treatment was calculated to be at least 80.5%.…”

Section: Continuation Treatmentmentioning

confidence: 99%

“…moclobemide was as effective as at 100 mg t.i.d. (89). At daily moclobemide doses for up to 900 mg /d no dietary tyramine restriction is required (68).…”

Section: Dosage and Administrationmentioning

confidence: 99%

“…There is a lack of controlled clinical studies addressing the long-term efficacy of moclobemide. Nevertheless, there is a limited but consistent evidence to support the long-term efficacy of moclobemide in depressed patients (89,143,162,164). Refractory depression might profit from the combination of moclobemide and clomipramine or a SSRI, though this combination is associated with the risk of the potentially fatal serotonin syndrome.…”

Section: Place In the Management Of Depression And Anxiety Disordersmentioning

confidence: 99%

See 1 more Smart Citation

Moclobemide: Therapeutic Use and Clinical Studies

Bonnet¹

2003

CNS Drug Reviews

195

View full text Add to dashboard Cite

Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in anxiety disorders. Nearly all meta-analyses and most comparative studies indicated that in the acute management of depression this drug is more efficacious than placebo and as efficacious as tricyclic (or some heterocyclic) antidepressants or selective serotonin reuptake inhibitors (SSRIs). There is a growing evidence that moclobemide is not inferior to other antidepressants in the treatment of subtypes of depression, such as dysthymia, endogenous (unipolar and bipolar), reactive, atypical, agitated, and retarded depression as with other antidepressants limited evidence suggests that moclobemide has consistent long-term efficacy. However, more controlled studies addressing this issue are needed. For patients with bipolar depression the risk of developing mania seems to be not higher with moclobemide than with other antidepressants. The effective therapeutic dose range for moclobemide in most acute phase trials was 300 to 600 mg, divided in 2 to 3 doses. While one controlled trial and one long-term open-label study found moclobemide to be efficacious in social phobia, three controlled trials subsequently revealed either no effect or less robust effects with the tendency of higher doses (600 -900 mg /d) to be more efficacious. Two comparative trials demonstrated moclobemide to be as efficacious as fluoxetine or clomipramine in patients suffering from panic disorder. Placebocontrolled trials in this indication are, however, still lacking.A relationship between the plasma concentration of moclobemide and its therapeutic efficacy is not apparent but a positive correlation with adverse events has been found. Dizziness, nausea and insomnia occurred more frequently on moclobemide than on placebo. Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri-or heterocyclic antidepressants. Gastrointestinal side effects and, espe-97

show abstract

Moclobemide Twice Daily in the Treatment of Major Depressive Episode: A Double-Blind, Multicenter Comparison with Different Three-Times-Daily Dosage Schedules

Cited by 4 publications

References 0 publications

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression

Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials

Moclobemide: Therapeutic Use and Clinical Studies

Contact Info

Product

Resources

About